United Kingdom: Healthcare

Biotechnology and chemistry startups face a critical question when filing priority patent applications: how much experimental data is actually required? While the answer depends on the predictability of the technology, the European Patent Office's strict disclosure standards mean that insufficient technical support can invalidate priority claims entirely, leaving innovations vulnerable to competitor filings and prior art that emerges during the assumed protection period.

ValiRx's subsidiary Cytolytix has received positive signals from the European Patent Office regarding patent protection for its polyleucine-based anti-cancer peptides, raising questions about why the company is publicly announcing these intellectual property developments. The strategic timing and nature of these announcements may reveal important insights about the company's approach to attracting investment and licensing partners in the competitive biotechnology sector.

Human papillomavirus vaccination has dramatically reduced cervical cancer rates in young women across the EU, but could the same approach work for HPV-positive oropharyngeal cancer, which has tripled in incidence among Scandinavian men over three decades? As gender-neutral vaccination programs roll out and immunotherapy strategies evolve, the landscape for treating and potentially preventing HPV-driven head and neck cancers is undergoing a fundamental transformation.

Investigations into NHS paediatric audiology services have revealed systemic failures affecting hundreds of children, including delayed assessments and missed hearing loss diagnoses that may have impacted speech, language and educational development. Families affected by these failures in care may have legal options to pursue compensation where delays caused avoidable harm and lost opportunities for early intervention. Understanding the scope of these failures and the potential consequences for children's d

The European Patent Convention allows medical use claims for substances and compositions, but not devices. Recent case law has shifted the approach to determining what qualifies as a "substance or composition," moving away from mode-of-action analysis toward examining the claimed material itself. This evolution raises critical questions about claim drafting and the scope of patent protection for medical technologies.

As artificial intelligence transforms healthcare and life sciences, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) is shaping a new regulatory framework through its Call for Evidence and AI sandbox initiatives. These developments signal a shift toward lifecycle-based oversight, continuous monitoring, and principles-based regulation that balances innovation with patient safety and accountability.

A personal injury solicitor shares her firsthand experience of catastrophic injury during pregnancy, offering unique insight into the challenges of hospital treatment, rehabilitation, and recovery. Her story demonstrates how professional legal support combined with proper rehabilitation can help rebuild quality of life after life-changing accidents.

The Ockenden Review has uncovered serious and repeated concerns in maternity care at Nottingham University Hospitals, spanning thousands of cases from 2012 to 2025. With findings identifying systemic failures in patient safety, clinical practice, and organisational culture, the review raises critical questions about whether improved care could have prevented devastating outcomes for affected families.

Half of women working in law say the demands of their job are unsustainable for their long-term health, according to new research which canvassed the views of more than 500 female legal professionals.